---3

2555
1 2555 10,000

7 6

11000
. . .

.
.
.

.
.

.
.

.
.
.
.
.
.

.
.

.
.
.
.

.
.

.
.

.

-- 3. - - . . 2555
128 .

ISBN

1
.. 2556 100

50

20

2553 47,000 128


158
56 60 65
47
90
25
40

2554

2555

()
()
2555


1

1.1

1.2

1.3

1.4



1.5

1.6

1.7



1.8





1.9





1.10



1.11



1.12



1.13

14
16
19
20
21
23
24

24

25
26
27
28
28

1.14


1.15

1.16
1.17 ?

?
1.18
1.19

2

2.1

2.2

2.3



2.4



2.5

2.6

2.7

2.8

2.9



2.10

29
30
31

32
33
36

38
44
45
46
49
50
52
53
54
55

2.11

2.12
2.13
2.14


2.15

2.16

2.17

2.18
2.19

2.20

2.21

2.22

2.23
2.24

2.25

55
56
57
57
58
59
60
62
62
63
64
65
66
67
67

3

3.1
70

3.2




72

3.3

73

3.4


73

3.5


74

3.6

4 75

3.7 beyond-use date


75

3.8

30 C


76

3.9

4


77

3.10




78

3.11


79

3.12

1


79

3.13
80

3.14


3.15


3.16

3.17

3.18 3

3.19

3.20

4

4.1



4.2



4.3



4.4



4.5

81
83
84
85
85
87

87

90
93
94
96
97

4.6


4.7

4.8

4.9

4.10

4.11

4.12

5

5.1





5.2



5.3







5.4

98
98
99
99
100
101
102

104
105

107
108

5.5



5.6




5.7

5.8

5.9

6

6.1

6.2

6.3

6.4



6.5

6.6

6.7



6.8

108

109
110
111
112
114
115
116
118
119
119
120
121

1.

2.
14 :

3.




4.



5.


6.


7.



8.

9.

10.

-- 3

: 15

/








16 :

1.











2.




-- 3

: 17




3.

4.

5.




6.

7.


8.



18 :

9.

4

1.







2.



2
2


-- 3

: 19



3.

4.

5 (5R) (right patient)
(right medication) (right dose) (right time)
(right route)

20 :

1.

2.

3.

4.

5.

( )

-- 3

: 21





1.
...





2.

3.





4.





5.
22 :

1.
-

2. -


3.

4.
-- 3

: 23

24 :

-- 3

: 25

26 :

-- 3

: 27

()

/



28 :

-- 3

: 29

1
2
4-5

/

30 :

-- 3

: 31

?
?

?

(indication)

32 :

-- 3

: 33

 . .

?

?

:

1
34 :

( 1)

-
/, /
/

-- 3

: 35

36 :

-- 3

: 37

38 :

(Disintegrating tablets)

( ^_^)
2 3




4-6
-- 3

: 39

(Chewable tablets)

40 :

(Effervescent tablets)

(blister pack)

-- 3

: 41

(Lozenges)

(Sublingual and buccal tablets)

()

5 2

42 :

(Coated tablets)

(coated tablets)
(sugar coated) (film coated)

-- 3

: 43

...... .........

(
)

(enteric-coated tablet)







(Sugar coating tablet)





(Ciprofloxacin)

44 :

(extended-release tablet)

-- 3

: 45

 (Pellet)


(Omeprazole)


(NG Tube)

DM, GP, DA, PSE, SR, SA, CR/CRT, LA,
MR, TD/TR, XL, XR/ER, OROS, Contin

5001,000


46 :

(unit dose package)




4
10 28
2

1.

-- 3

: 47





(
)


2.

10






1-2

48 :

2448
1

(ampule) (vial)
(single dose)


(single dose)
(multi dose)

-- 3

: 49

2

2

1. (Metered-dose inhaler, MDI)

(chlorofluorocarbon: CFC)




50 :

( & )


2. (Dry powder
inhaler)

(Nebulizer)

2

1. (Preventer, controller)

2. (Reliever)

-- 3

: 51

52 :

( )

10 .




(Hellebore)

-- 3

: 53

1.

2.

5

3.


4.

5.

15 - 20

54 :

(steroid)

(polyethelene glycol: PEG)

(Oral Candidiasis)

3-5
..

-- 3

: 55



1.

2.

56 :

15

soft
gelatin capsule
(collagen)





(xanthan gum)

(soft gelatin
capsule) (nifedipine)

-- 3

: 57

 (extended-release formulation)

25

7-14

7-10

7
1
1 2

Amoxycillin + Clavulanic acid Augmentin, Amoksiklav,

Curam 7

2 8 C

Amoxycillin 250 mg dry syrup (Siam pharmaceutical)

7 2 8 C
58 :

Unasyn 14 2 8 C
Distaclor 14 2 8 C
Zinnat 10 2 8 C
Colistin 7 2 8 C
Omnicef 7
18 25 C
Cefspan 14
25 C
Zithromax 10
25 C

-- 3

: 59

1.


2.

3.

4.



5.

(cardiac arrest)
60 :

(circulatory collapse) (anaphylactic reactions)

(convulsion) (bronchospasm)
(adrenaline), (atropine), /
(dopamine/dobutamine)

( 2 )

2

72
12


85 (
24 )


-- 3

: 61

(premixed insulin)
100 /.


(Mixtard) 70/30 (
30/ 70), (Humalog Mix)
25 ( 25/ 75)

2
62 :

(.)





()


(phytoestrogen)

(estrogen)

-- 3

: 63

2555








2554

2555
2

(Pseudoephedrine)

2 2541
2

(Pseudoephedrine)
64 :

1 14

..1988

(ORS)


()

-- 3

: 65





0.9% , 0.45% , 5%, 10%
,

5 3

1
6

66 :

5 (solution) (syrups)
(suspension) (tincture)
(Emulsion)



2

(Directly Observed Treatment:
DOTS)


DOTS
DOTS
-- 3

: 67


(2 )

68 :

-- 3

: 69

1.

1

2. -

3.


500 , 325
70 :

4.



5.
1 3
2 10 6

6.
/

7.




8.

-- 3

: 71



..2510

1.

2. Reg.No

3.


4.
Lot No., Cont.No.,Batch No. L , C , L/C ,
B/C

5.

6. Mfd. Mfg
date. 5

Exp.Date Expiration Date

7.



8.

72 :

-- 3

: 73

,
, ,

()

74 :

beyond-use date

,



(
)




6
6
240
1 (15 ) 3 1
5

beyond-use date

(
,
-- 3

: 75

 )

1
, 6


beyond-use date expired date ()

30 C

76 :

30



30

(Psychotropic Substances)

4
-- 3

: 77




(....)

3
3
2

78 :

2 4 6





1 1

( 1) 2 5
10
2


-- 3

: 79


()

indication 2552

80 :

2









-- 3

: 81


1.

2. /

3.


4.






5.

6.

7.

82 :

1
(doxazosin)

-- 3

: 83

19
2554
2 4 2555

84 :

.. 2522 ( 2 .. 2528 3
.. 2530)








5
-- 3

: 85

 .. 2522

1. 1
()

2. 2

3. 3


3

4. 4
1

5. 5


3

86 :

?


( 5) .. 2530 1-48

2 1
-- 3

: 87

(Insulin-dependent diabetes mellitus (IDDM))

2 (Noninsulin-dependent diabetes mellitus (NIDDM))

2

88 :

-- 3

: 89









...

(general appearance) (vital signs)






(

)

(..

)
90 :

35.8
37.3

35.3-37.8

37.8







1 60-100



140







120/80



110/70 - 120/80






1 12-18

10



20

-- 3

: 91

1. (fasting plasma glucose/fasting blood
sugar, FPG/FBS)







8
12 - 6 60-100
7 70-100



92 :

2. (blood urea nitrogen, BUN)

5-18 7-20

3. (serum creatinine, Cr)

18 0.61.3

......

(Hepatotoxicity)
-- 3

: 93

 2-5

3-10

8-10 ( 500 ) 1

94 :

(angiotensin converting enzyme)




1-4

-- 3

: 95

2-5
50-70


3

96 :

,







30
30


2

-- 3

: 97

(Fasting plasma glucose: FPG
Fasting blood sugar: FBS)
8


(Hemoglobin A1C: HbA1C)
120
3

1 - 2
98 :

(HDL: high density lipoprotein)
,



(LDL: low density lipoprotein)

8 150 100

500
100

-- 3

: 99

1.

2.

3.

4.

5.

6.

7.


8.

8

100 :

12

8 - 12

-- 3

: 101

10

1.


2.

3.
10

4.

5.

102 :

-- 3

: 103

( )


1



555+




(Isotretinoin) (
)


104 :

()
(photosensitivity)

( 15
(antioxidants)
,

(drug interaction)

-- 3

: 105






(fatal drug interaction)

3-6


106 :

2-3

3-4

-- 3

: 107

..


108 :

(drug allergy)

-- 3

: 109


(rhabdomyolysis)
(< 1%)

(colchicine),
(gemfibrozil)
, , ,

(creatine kinase)

(orthostatic hypotension) 10 20

3



110 :

(doxazosin,
prazosin), (methydopa)

1-2

(allopurinol)

(acetazolamide)


1-2
-
-- 3

: 111

2

1.

2. (side effect)

112 :

-- 3

: 113


2554




2554

114 :

80
1 18

70
23
30



1

-- 3

: 115

-- 2
555+

(>65 )
















12












116 :

12


G6PD





















-- 3

: 117

118 :

-- 3

: 119

7
4.4
2.4

(http://www.gotoknow.org/blogs/posts/438856)
120 :

-- 3

: 121


1.


2.

3.

4.
5.


6.

7.


8.



9.

... [homepage on the Internet].

; date unknown Available from: http://www.medicthai.com/admin/
news_cpe_detail.php?id=651. Accessed May 10, 2012
. . :
;2549. 1-8.
, . ... Adverse Drug Reaction.
: . 2549.
Available from http://www.cgd.go.th .Accessed May 10, 2012.
:
9 . Available from: http://www.
gotoknow.org/ blogs/ posts/423713. Accessed May 15, 2012.
. .
.
[internet]. : [updated 2012May 3; cited
2012 May15]. . Available from: http://tnf.thaifda.com/
--indication-sid24.aspx
. . :
(Tamper-Evident Packaging): 3 Available
from: http://www.pharmacy.mahidol.ac.th/mobile/TH/knowledge.php?id=60.
Accessed May 12, 2012.
. (Emergency Drugs). : , ,
. . . 2.
: (), 2549: 203-27.

122 :

10. [homepage on the internet]. :

place unknown. publisher unknown; date unknown [date unknown; cited 2012 May
10]. Available from: http://www.pharmacy.mahidol.ac.th/thai/knowledgeinfo.
php?id=54.
11.
. ..2554.
. 2554.
12. Transdermal Drug Delivery System. .
. R&D Newsletter 16 2 - 2552. Available:
www.gpo.or.th/rdi/html/RDINewsYr16No2/6.pdf. Accessed May 21, 2012.
13. Available from:http://wwwapp1.fda.moph.go.th/drug/
zone_gmp/ files/STERILE.PDF. Accessed May 20,2012
14. ..
. . [cited 20 May 2012].
Available from: http://www.childrenhospital.go.th/main/ph/PEOPLE/MEDICINE/
026.htm
15. . -
(2) . Available from: http://www.si.mahidol.
ac.th/sidoctor/e-pl/articledetail.asp?id=293. Accessed May 20,2012
16. . 2012. ?
. Available from: http://languhospital.com/articles.asp?newsid =21&CatID=.
Accessed May 20,2012.
17. . . ...
!() Available From http://www.si.mahidol.ac.th/sidoctor/e-pl/admin/
article_files/821_1.pdf. Accessed May 20,2012.
18.
(.. 2550) Available from: http://www.fda.moph.go.th/fda-net/html/
product/drug/ label-d.htm. Accessed May 19,2012.
19. Available from: http://www.gpo.or.th/
rdi/html/stability.html. Accessed May 27,2012.
20. Available from: http://www.
childrenhospital.go.th/main/ph/PEOPLE/MEDICINE/049.htm. Accessed May 27,2012.
-- 3

: 123

21. Available from: http://

www.fda.moph.go.th/prac/watch/answer/drug_faq.shtml. Accessed May 12,2012
22. . www.dmsc.moph.go.th/webroot/narcotics/other.htm
.
23. - :: ::BUREAU.drug.fda.moph.
go.th/drug/zone_service/ser002.asp
24. . . : .
() 3 . ;
2546 57-63.
25. . . : ,
, .()
3 . ; 2546 65-106.
26. . .
: : ()
; 2548. 78-134.
27. . cough. : .
() manual of medical diagnosis 1:
; 2552 124-133.
28. . Angiotensin converting enzyme inhibitors. :
.() A Practical Guide
to Pharmacovigilance 1.:
; 2547 91-99.
29. . .
2554;10(2): 1-8.
30. . .
: : ()
; 60-74.
31. - []. : ;
[ 10 2555]. [2 ]. : http://web.ku.ac.th/saranaroo/chap
3a.htm
32. []. :
; [ 10 2555]. [3 ]. : http://www.pharmacy.
mahidol.ac.th/thai/knowledgeinfo.php?id=83

124 :

33. . . HDL LDL . . 2542; 245: 245-6.

34. . (2551). .
18 2555, :
35. . Photosensitivity and sunburn. R&D newsletter 2553;4:15-20.
36. . . : , ,
- , . . 3.
: ; 2554. 196-212.
37. Available at: http://www.yrh.
moph.go.th/deparment/blood_bank51/ferrous.htm. Accessed May 21, 2012
38. . . : ,
, , . .
3. : ; 2554. 170-94.
39. Drug induce nephrotoxicity. Available from: http://www.
elib-online.com/physicians/drugs/drug_induce_nephropathies.pdf. Accessed
May 12, 2012
40. . Nephrolithiasis ( ) Dispensing
& Pharmacotherapeutic I
41. Available from: http://
www.gotoknow.org/blogs/posts/438856. Accessed May 28, 2012.
42. Lee RE. Effervescent tablets: key facts about a unique, effective dosage form.
Available from: http://www.amerilabtech.com/docs/EffervescentTablets &Key
Facts.pdf. Accessed May 20, 2012.
43. Quan K. The patients role and reaponsibilities. Available from: http://www.
netplaces.com/ health-care-careers/understanding-the-patients/the-patients role-and-responsibilities.htm. Accessed May 18, 2012.
44. American Medical Association. AMA code of medical ethics: opinion 10.02-patient
responsibilities. Available from: http://www.ama-assn.org/ama/pub/physician resources/medical-ethics/code-medical-ethics/opinion1002.page. Accessed
May 18, 2012.
45. Senthil Kumar K. Pharmaceutical technology II. Available from: http://www.scribd.
com/doc/33275103/Tablets-solid-dosage-form. Accessed May 15, 2012.
46. Mixtard 30 HM [package insert]. Bagsvaerd: Denmark; 2006.
-- 3

: 125

47. Humalog Mix 25 [package insert]. Fegersheim: France; 2007.

48. Micromedex Healthcare Series, (Electronic version). Thomson Micromedex,
Greenwood Village, Colorado, USA.Doxazosin. Available from: http://www.
thomsonhc.com (Accessed on May 11, 2012).
49. Lacy CF, Armstrong LL, Goldman MP and Leonard L. Drug Information Handbook
International. 19th ed. Lexi-Comp Inc, Ohio, USA: 525-7, 2010-2011
50. http://drug.fda.moph.go.th/zone_service/files/ser001_03.asp
51. http://drug.fda.moph.go.th/zone_law/law020.asp
52. American Diabetes Association. Standards ofMedical Care in Diabetes. Diabetes
Care 2012;35(Suppl 1):S1163.
53. National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III). Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:31433421.
54. Triplitt CL, Reasner CA and Isley WL. Diabetes Mellitus. In: Dipilo JT, Talbert RL,
Yee GC, Wells BG and Posey LM, editors. Pharmacotherapy A Pathophysiologic
Approach. New York: McGraw-Hill; 2008. p. 1205-42.
55. Clarkson MR, Friedewald JJ, Eustace JA, Rabb H. Acute kidney injury. In: Brenner
BM, eds. Brenner and Rectors The Kidney. 8th ed. Philadelphia, Pa: Saunders
Elsevier; 2008:chap 29.
56. Fowler GC, Vasudevan DA. Type2 Diabetes Mellitus: Managing Hemoglobin A1C
and Beyond. SMJ. 2010; 103: 911-6.
57. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults. Executive Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA.
2001;285:24862497.
58. Syncope in the Elderly (Weerasak Muangpaisan, M.D. : Department of Preventive
and Social Medicine , Siriraj hospital)
59. Riedl, M.A. and Casillas, A.M. Adverse drug reactions: types and treatment options.
American Family Physician 2003; 68:1781-90.

126 :

60. Gruchalla, R.S. Drug allergy. Journal of Allergy and Clinical Immunology 2003;
111(2): S548-S558.
61. Vira T, Colquhorn M, Etchells E. Reconcilable differences: correcting medication
errors at hospital admission and discharge.
62. Wong JD, Bajcar JM, Wong GG, MH Alibhai S, Jin-Hyeun Huh, Cesta A, Pond GR,
and Fernandes OS. Medication reconciliation at hospital discharge: evaluating
discrepancies. Ann Pharmacother 2008;42:1373-9.
63. Viktil KK, Blix HS, Moger TA, Reikvam A. Interview of patients by pharmacists
contributes significantly to the identification of drug-related problems (DRPs).
Pharmacoepidemiology and drug safety 2006; 15:667-674.

-- 3

: 127